Detalhe da pesquisa
1.
Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.
Lab Invest
; 104(4): 100321, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38154497
2.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Int J Gynecol Cancer
; 34(4): 550-558, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38129136
3.
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Int J Gynecol Cancer
; 33(12): 1966-1969, 2023 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37935524
4.
Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6).
Int J Gynecol Cancer
; 31(7): 1075-1079, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34226291
5.
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
Int J Cancer
; 146(2): 439-448, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31381147
6.
LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial.
Int J Gynecol Cancer
; 30(10): 1548-1553, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32938723
7.
Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group.
Arch Gynecol Obstet
; 301(5): 1267-1274, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32277253
8.
Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7).
Int J Gynecol Cancer
; 26(9): 1636-1641, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27654266
9.
What is the evidence for lymphadenectomy in presumed early ovarian cancer?
Arch Gynecol Obstet
; 299(1): 1-5, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30374648
10.
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
J Clin Oncol
; 41(4): 893-902, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332161
11.
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
Gynecol Oncol
; 126(2): 236-40, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22564713
12.
Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer.
J Cancer Res Clin Oncol
; 138(11): 1945-50, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22760213